Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director George Jenkins sold 13,152 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $133.69, for a total transaction of $1,758,290.88. Following the transaction, the director owned 146,964 shares in the company, valued at $19,647,617.16. The trade was a 8.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Price Performance

Shares of PVLA stock opened at $120.30 on Friday. The stock has a 50 day moving average price of $145.44 and a 200 day moving average price of $134.33. Palvella Therapeutics, Inc. has a 52-week low of $68.96 and a 52-week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, equities analysts anticipate that Palvella Therapeutics, Inc. will post -6.40 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Chardan Capital initiated coverage on Palvella Therapeutics in a report on Monday, September 21st. They issued a “buy” rating and a $240.00 price objective for the company. HC Wainwright cut their target price on shares of Palvella Therapeutics from $270.00 to $246.00 and set a “buy” rating for the company in a report on Monday, October 12th. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Finally, William Blair initiated coverage on shares of Palvella Therapeutics in a research report on Friday. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $209.79.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: William Blair initiated coverage with an Outperform rating. The new bullish analyst coverage adds credibility to Palvella’s long-term opportunity and may support investor interest in its rare-disease pipeline. William Blair initiates coverage
• Positive Sentiment: New pediatric analyses for QTORIN rapamycin showed improvements in disease severity and lesion characteristics. Results from the Phase 3 SELVA and Phase 2 TOIVA studies highlighted improvements in children with microcystic lymphatic malformations and cutaneous venous malformations. QTORIN could potentially become the first FDA-approved treatment for these conditions, although the therapy remains investigational. Palvella pediatric QTORIN analyses
• Neutral Sentiment: HC Wainwright retained its Buy rating and $246 price target. Its 2027 quarterly estimates imply continued losses—$2.40, $2.59, $4.16 and $4.36 per share from the first through fourth quarters—underscoring that profitability remains distant despite the optimistic valuation target. HC Wainwright PVLA estimates
• Negative Sentiment: Director George Jenkins sold an additional 13,152 shares for approximately $1.76 million. This followed a sale of 7,174 shares worth about $935,000, with both transactions conducted under a pre-arranged Rule 10b5-1 plan. Repeated insider selling can weigh on sentiment, even though the scheduled nature of the trades reduces their signaling value. George Jenkins insider sale

Institutional Trading of Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $140,343,000. First Light Asset Management LLC raised its holdings in Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares during the period. Jennison Associates LLC lifted its position in Palvella Therapeutics by 65.3% in the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after buying an additional 253,128 shares during the last quarter. Summit Partners Public Asset Management LLC increased its position in shares of Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after acquiring an additional 354,525 shares during the last quarter. Finally, Primecap Management Co. CA purchased a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $39,150,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.